Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12551173 | 0.89 | SMN1; SMN2 (0.43) | SMN1; SMN2IRAK4HRH3RORC | |
| SCHEMBL31378935 | 0.80 | LMNA (0.34) | SMN1; SMN2POLB | |
| SCHEMBL12551174 | 0.79 | SMN1; SMN2 (0.45) | SMN1; SMN2IRAK4HRH3POLB | |
| SCHEMBL1286689 | 0.78 | KDM4E (0.43) | SMN1; SMN2IRAK4POLBRORC | |
| SCHEMBL15014627 | 0.78 | KDM4E (0.43) | SMN1; SMN2IRAK4POLBRORC | |
| SCHEMBL954379 | 0.78 | SMN1; SMN2 (0.37) | SMN1; SMN2IRAK4HRH3RORC | |
| SCHEMBL18502943 | 0.78 | SMN1; SMN2 (0.37) | SMN1; SMN2IRAK4HRH3RORC | |
| SCHEMBL12551233 | 0.77 | SMN1; SMN2 (0.44) | SMN1; SMN2POLB | |
| Hydrochloric Acid SCHEMBL26678224 | 0.77 | SMN1; SMN2 (0.36) | SMN1; SMN2IRAK4HRH3 | |
| SCHEMBL2114984 | 0.76 | GPR119 (0.40) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-05-29 | — | — | US | disclosed |
| WO-2025030163-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | IGF1R, TRHR, TSHR | SMN1; SMN2 4102/4885IRAK4 440/4885EPHX2 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.